Poster Session A

Poster Session A
Sunday, October 16
4:30 p.m.-6:30 p.m.

In alphabetical order, not board assignment order

• A CGH/gene expression screen for factors that abrogate MYC-induced apoptosis during lung tumorigenesis. Thaddeus D. Allen, J. Michael Bishop. University of California, San Francisco, CA.
• A frequent novel mutation in the FLT3 gene in acute myeloid leukemia. Nejat Dalay, Nazli Ucunoglu. Istanbul University Oncology Institute, Istanbul, Turkey.
• A Sleeping Beauty transposon mutagenesis screen suggests involvement of the imprinted Dlk1-Dio3 domain in hepatocellular carcinoma development. Jesse D. Riordan1, Adam J. Dupuy1, Vincent W. Keng2, Barbara R. Tschida2, Kelly M. Podetz-Pedersen2, Lionel Lim3, Neal G. Copeland4, Nancy A. Jenkins4, Andrei Goga3, David A. Largaespada2. 1University of Iowa, Iowa City, IA, 2University of Minnesota, Minneapolis, MN, 3University of California, San Francisco, CA, 4Institute of Molecular and Cell Biology, Singapore.
• A transposon-based genetic screen in mice to identify drivers of histiocytic sarcomagenesis. Raha Allaei, Timothy K. Starr, David A. Largaespada. University of Minnesota, Minneapolis, MN.
• An integrated approach to the identification and functional validation of therapeutic targets in colorectal cancers. Michael Barrett1, Elizabeth Lenkiewicz1, Lisa Evers1, Tara Holley1, Ramesh Ramanathan1, Nadav Dujovny2, Craig Webb2, Jeffrey MacKeigan2. 1Translational Genomics Research Institute, Phoenix, AZ, 2Van Andel Research Institute, Grand Rapids, MI.
• Cancer genome-based multigenic models of colon cancer in Drosophila. Erdem Bangi, Alex Teague, Ross Cagan. Mount Sinai School of Medicine, New York, NY.
• Center for Personalized Cancer Treatment: A Dutch collaborative group to implement next-generation sequencing in clinical trials. Marco J. Koudijs1, Martijn P.J.K. Lolkema1, Paul J. van Diest2, Rene Bernards3, Edwin Cuppen4, John W.M. Martens5, Jan H.M. Schellens3, Stefan Sleijfer5, Emile E. Voest1. 1University Medical Center Utrecht, Dept of Medical Oncology, Utrecht, The Netherlands, 2University Medical Center Utrecht, Dept. of Pathology, Utrecht, The Netherlands, 3Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 4Hubrecht Institute and UMC Utrecht, Dept. of Medical Genetics, Utrecht, The Netherlands, 5Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
• Characterization of BRAF and NRAS models of zebrafish melanoma through exome sequencing. Jennifer L. Yen1, Richard White2, Jenny Richardson3, Amy Capper3, Ian Jackson3, Len Zon2, Jim Lister4, Liz Patton3, Derek Stemple1, Andy Futreal1. 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 2Dana-Farber Cancer Institute, Boston, MA, 3Medical Research Council Human Genetics Unit, Edinburgh, United Kingdom, 4Virginia Commonwealth University, Richmond, VA.
• Detection of low-level EGFR T790M mutation in lung cancer tissues. Sug Hyung Lee, Ji Eun Oh, Nam Jin Yoo. The Catholic University of Korea, Seoul, Korea (Rep.).
• Differential expression of genes and induction of LGR5 by hydrogen peroxide in colon cancer cells. Sung-Hee Kim, Ja-Lok Ku. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea (Rep.).
• Downregulation of NPRL2 in colon cancer. Nur Buyru, Beste Yogurtcu. Cerrahpasa Medical Faculty Department of Medical Biology, Istanbul, Turkey.
• Evaluation of castPCR™ technology for tumor mutation detection. David I. Lichter, Russell M. Walker, Elena S. Izmailova. Millennium Pharmaceuticals, Inc., Cambridge, MA.
• Exome sequencing and integrative mutational profiling of lethal castrate-resistant prostate cancer. Catherine S. Grasso1, Sang Y. Chun1, John R. Prensner1, Javed Siddiqui1, Lee Sam1, Matthew Iyer1, Matt Anstett2, Terrence Barrette1, Chandan Kumar-Sinha1, Sooryanarayana Varambally1, Rohit Mehra1, Dan R. Robinson1, Nallasivam Palanisamy1, Daniel R. Rhodes1, Kenneth J. Pienta1, Arul M. Chinnaiyan1, Scott A. Tomlins1, Yi-Mi Wu1, Dhanasekaran M. Saravana1, Michael J. Quist1, Xuhong Cao1, Xiaojun Jing1, Robert J. Lonigro1, J. Chad Brenner1. 1Michigan Center for Translational Pathology, Ann Arbor, MI, 2Compendia Bioscience, Ann Arbor, MI.
• Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Kai Wang1, Wai Yin Tsui2, Siu Po Lee2, Siu Lun Ho2, Anthony K.W. Chan2, Grace H.W. Cheng2, Peter C. Roberts1, Paul A. Rejto1, Neil W. Gibson1, Junsuo Kan2, David J. Pocalyko1, Mao Mao1, Jiangchun Xu1, Suet Yi Leung2, Siu Tsan Yuen2, Stephanie T. Shi1, Kent Man Chu2, Simon Law2, Tsun Leung Chan2, Shengyan Kan1, Annie S.Y. Chan2. 1Pfizer, Inc., San Diego, CA, 2The University of Hong Kong, Hong Kong, China.
• Exome sequencing reveals frequent somatic mutation events in MAP3K5/9 that contribute to temolozolomide resistance in metastatic melanoma. Ken Dutton-Regester1, Mitchell S. Stark1, Victoria Zismann2, Sonika Tyagi1, Irene Newsham3, YuanQing Wu3, Jane Palmer1, Thomas Pollak1, David Youngkin2, Bradford R. Brooks4, Chris Sereduk2, Catherine Lanagan1, Susan L. Woods1, Christopher Schmidt1, Bostjan Kobe5, Hongwei Yin2, Kevin M. Brown6, Richard Gibbs3, Jeffrey Trent2, Nicholas K. Hayward1, Michael Gartside1, Vanessa F. Bonazzi1, Lauren G. Aoude1, Donna Muzny3, Donald Chow2, Jonathon J. Ellis5, Jeffrey Reid3. 1Queensland Institute of Medical Research, Brisbane, Australia, 2Translational Genomics Research Institute, Phoenix, AZ, 3Baylor College of Medicine, Houston, TX, 4Van Andel Research Institute, Grand Rapids, MI, 5Institute of Molecular Biosciences, Brisbane, Australia, 6National Cancer Institute, Gaithersburg, MD.
• Exploring epigenomic correlates of structural aberrations in cancer genomes using the breakout algorithm and the genboree cancer toolset. Cristian Coarfa1, Christina Stewart Pichot1, Andrew R, Jackson1, Arpit Tandon1, Sriram Raghuraman1, Sameer Paithankar1, Adrian V. Lee2, Sean E. McGuire1, Aleksandar Milosavljevic1. 1Baylor College of Medicine, Houston, TX, 2University of Pittsburgh, Pittsburgh, PA.
• Exploring the underlying epigenetic changes in clear cell renal cell carcinoma. Kathryn E. Hacker, A. Rose Brannon, Oishee Sen, C. Ryan Miller, W. Kimryn Rathmell. University of North Carolina, Chapel Hill, NC.
• Formalin-fixed paraffin-embedded (FFPE) tissue in high-throughput genetic analyses. Heli J. Lehtonen1, Yilong Li1, Eevi Kaasinen1, Mervi Aavikko1, Alexandra Gylfe1, Päivi Lahermo2, Pekka Ellonen2, Lauri A. Aaltonen1. 1University of Helsinki, Helsinki, Finland, 2Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland.
• From cancer genomes to tumors: Polygenic validation of human cancer mutations by in vivo tumorigenesis. Su Kit Chew, Dong Lu, Qin Su, Pentao Liu, P. Andrew Futreal. Wellcome Trust Sanger Institute, Hinxton, England.
• Functional genomics approaches and integration of aCGH and epigenetic data sets in solid tumors. Galen Hostetter1, Michael Syring2, Aprill Watanabe2, Bodour Salhia2, Janine LoBello2, John Carpten2. 1Translational Genomics Research Institute and Van Andel Research Institute, Grand Rapids, MI, 2Translational Genomics Research Institute, Phoenix, AZ.
• Genome-wide evaluation in head and neck cancer families. Fernanda Bernardi Bertonha, Luiz Paulo Kowalski, Benedito Mauro Rossi, Erika Maria Monteiro Santos, Maria Isabel Waddington Achatz, Silvia Regina Rogatto. A.C. Camargo Hospital, Sao Paulo, Brazil.
• Genome-wide molecular and functional analysis identified LNX2 as a novel gene involved in colorectal carcinogenesis. Jordi Camps1, Michael B. Ghadimi2, Tim Beissbarth2, Michael J. Difilippantonio1, Natasha J. Caplen1, Thomas Ried1, Jason J. Pitt1, Georg Emons2, Amanda B. Hummon1, Chanelle M. Case1, Marian Grade2, Tamara L. Jones1, Quang T. Nguyen1. 1National Cancer Institute, Bethesda, MD, 2University of Medicine Göttingen, Göttingen, Germany.
• Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Yu Zhang1, Daniel J. Malkin1, Donna Neuberg2, Stefano Monti3, Cosmas C. Giallourakis4, Monica Gostissa1, Frederick W. Alt1, Roberto Chiarle1, Richard L. Frock1, Susanna M. Lewis1, Benoit Molinie4, Yu-Jui Ho1, Darienne R. Myers1, Vivian W. Choi1, Mara Compagno1. 1Harvard Medical School, Boston, MA, 2Dana-Farber Cancer Institute, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Massachusetts General Hospital, Boston, MA.
• Genomic dissection of the EGFR/PI3K pathway reveals drivers of pathway activation in head and neck cancers. Luc Morris, Barry Taylor, Stephanie Eng, Cameron Brennan, Bhuvanesh Singh, Adriana Heguy, Agnes Viale, Ian Ganly, Timothy Chan. Memorial Sloan-Kettering Cancer Center, New York, NY.
• Genomic imbalances driving gene expression in genes mapped on chromosome 3 are related to worse prognosis in penile carcinomas. Ariane F. Busso1, Fábio A. Marchi2, Gustavo C. Guimarães1, Isabela W. Cunha1, Fernando A. Soares1, André L. Carvalho3, Cristovam Scapulatempo Neto3, José Vassallo4, Silvia R. Rogatto5. 1A.C. Camargo Hospital, São Paulo, Brazil, 2University of Sao Paulo, São Paulo, Brazil, 3Barretos Cancer Hospital, Barretos, Brazil, 4University of Campinas, Campinas, Brazil, 5São Paulo State University, Botucatu, Brazil.
• Identification of complex oncogene signatures in human cancer specimens and cell lines. Stephen P. Ethier, Govindaraja Atikukke, Ramsi Haddad. Wayne State University, Detroit, MI.
• Identification of novel biological and clinical markers for CRC by transcriptome analyses. Trude H. Ågesen1, Ragnhild A. Lothe1, Anita Sveen1, Stine A. Danielsen1, Lina Cekaite1, Marianne A. Merok1, Guro E. Lind1, Espen Thiis-Evensen2, Arild Nesbakken3, Rolf I. Skotheim1. 1The Norwegian Radiumhospital, Oslo University Hospital, Oslo, Norway, 2Rikshospitalet, Oslo University Hospital, Oslo, Norway, 3Aker, Oslo University Hospital, Oslo, Norway.
• Identification of novel molecules by gene array that determine DNA vs. RNA damage in the mechanism of action of thymidylate synthase (TS) inhibitors in colon carcinoma. Mohammad Azhar Aziz1, Janet Houghton2. 1King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, 2Cleveland Clinic Lerner Research Institute, Cleveland, OH.
• Illuminating the cancer kinome with comparative genomics. Gerard Manning, Michael Dacre, Eric Scheeff, Yufeng Zhai. Salk Institute for Biological Studies, La Jolla, CA.
• Integrating whole transcriptome sequence data and public databases for analysis of somatic mutations in tumors. Brian P. James, Amin A. Momin, Thomas C. Motter, Humam N. Kadara, Garth Powis, Ignacio I. Wistuba. University of Texas MD Anderson Cancer Center, Houston, TX.
• Longitudinal analysis of serum ALCAM during prostate cancer progression. Amanda G. Hansen, Ming Jiang, Shanna Arnold, Andries Zijlstra. Vanderbilt University, Nashville, TN.
• Mitochondrial DNA sequence variation and risk of pancreatic cancer. Ernest T. Lam1, Paige M. Bracci1, Elizabeth A. Holly1, Gregory J. Tranah2. 1University of California, San Francisco, CA, 2California Pacific Medical Center, San Francisco, CA.
• Nationwide registry-based approach to identify novel cancer susceptibility phenotypes and genes. Mervi Aavikko1, Eevi Kaasinen1, Yilong Li1, Pia Vahteristo1, Rainer Lehtonen1, Eero Pukkala2. 1University of Helsinki, Helsinki, Finland, 2Finnish Cancer Registry, Helsinki, Finland.
• Next-generation sequencing identifies androgen-regulated mitochondrial respiratory genes in prostate cancer cells. Kuniko Horie-Inoue1, Ken-ichi Takayama2, Kazuhiro Ikeda1, Satoshi Inoue2. 1Saitama Medical University, Hidaka, Saitama, Japan, 2University of Tokyo, Bunkyo-Ku, Tokyo, Japan.
• Optimizing molecularly-targeted cancer therapy using functional genomics. Trever Bivona1, Rafael Rosell2, Miquel Taron2, Gregory Hannon3, Charles Sawyers4. 1University of California, San Francisco, San Francisco, CA, 2Catalan Institute of Oncology, Barcelona, Spain, 3Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 4Memorial Sloan-Kettering Cancer Center, New York, NY.
• PIK3CA mutation status in HER2 positive breast cancer: Influences on PI3K-AKT signaling and response to therapeutic regimens. James Korkola1, Soulaiman Itani2, Richard Wooster3, Claire Tomlin2, Joe W. Gray1, Eric Collisson4, Nora Bayani5, Laura Heiser5, Nicholas Wang1, Heidi Feiler5, Paul Spellman1, Yi-Ling Lu6, Gordon Mills6. 1Oregon Health & Science University, Portland, OR, 2University of California, Berkeley, CA, 3GlaxoSmithKline, Collegetown, PA, 4UCSF, San Francisco, 5Lawrence Berkeley National Laboratory, Berkeley, 6University of Texas MD Anderson, Houston, TX.
• Putative enhancers at the 6q21 locus associated with radiation-induced cancers may regulate the radiation-response of PRDM1. Timothy Best, Shan Yu, Kenan Onel. The University of Chicago, Chicago, IL.
• Searching for mediators of sorafenib resistance in hepatocellular carcinoma by genomic approaches: The case of cyclin E1. Chiun Hsu1, Da-Liang Ou2, Ya-Chi Chang1, Yu-Che Cheng3, Ann-Lii Cheng1. 1National Taiwan University Hospital, Taipei, Taiwan, 2Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, 3Graduate Institute of Medical Technology, National Taiwan University College of Medicine, Taipei, Taiwan.